Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
GCC 0319: Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
Sponsor: Eli Lilly and Company
Listed as NCT00390182, this PHASE1/PHASE2 trial focuses on Gastrointestinal Neoplasms and Ovarian Neoplasms and remains completed. Sponsored by Eli Lilly and Company, it has been updated 10 times since 2003, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Sep 2019 — Apr 2020 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Oct 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
- University of Maryland, Baltimore
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Baltimore, United States
- • Hamilton, Canada